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Adhesions are common sequels of laparoscopic myomectomy (LM), even though they are much reduced
compared with laparotomy. Good surgical technique is the main principle to reduce post LM adhesion.
Based on electronic research of the PubMed database using speciﬁc keywords, barrier materials offer
promise for adhesion prevention at second look laparoscopy. However, pregnancy outcome when
inﬂuenced by adhesion formation after LM is unclear and warrants further investigation.
Copyright  2014, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
The frequency of myoma in women of childbearing age is
estimated to be 30e80%.1 The majority of women with myoma
are asymptomatic, but some causes are associated with menor-
rhagia, pelvic pain, or urinary symptoms that cannot be managed
by conservative treatment and therefore require surgery. For
women who wish to retain their fertility, myomectomy is an
alternative to hysterectomy. Myomectomy is one of the pelvic
surgeries that could cause a high rate of adhesion. The incidence
of adhesion formation after myomectomy was reported to be as
high as 83e94%, especially when the myomectomy incision
wounds were located at the posterior uterine wall.2e4 Operation
through laparoscopy had less postoperative pelvic adhesion
compared with laparotomic surgeries5 and therefore results in
less postoperative morbidity. However, there is controversy.
Open surgeries and laparoscopic surgeries were found to be
associated with similar rates of adhesion-related readmission in
gynecological patients.6 To date, no deﬁnitive strategies, rec-
ommendations, or guidelines have been established to prevent
the development of pelvic adhesion after myomectomy or lapa-
roscopic myomectomy (LM). The aim of this review is to present
clinical studies on various strategies to prevent postoperative
adhesion during LM.ts of interest relevant to this
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Peritoneal adhesions are pathological bands of connective tis-
sue. They may be formed congenitally or acquired, being developed
after inﬂammation or postoperation. The postoperative adhesion
formation has been distinguished as: type 1, de novo adhesion,
which occurs at sites with no adhesion prior to surgery; and type 2,
reformation adhesion,7 which occurs at sites with lysis of adhesion
during previous surgery. These adhesion bands may be a thin ﬁlm
of connective tissue, a thick ﬁbrous bridge containing blood vessels
and nerve tissue, or a direct contact between two organ surfaces.8
To quantify adhesions, the American Fertility Society (AFS)
modiﬁed the standardized American Society for Reproductive
System and developed an adhesion scoring recording system.9 In
this system, 23 individual abdominal and pelvic areas or 13 lower
pelvic locations were visualized for severity of adhesion (0, none; 1,
ﬁlmy, avascular; 2, vascular and/or dense; 3, cohesive) and extent of
total area or length of adhesion (0, none; 1, 25%; 2, 26e50%; 3,
>50%). Second-look laparoscopy (SLL) is a usual way to evaluate
postoperative adhesion. Accordingly, the incidence of type 1
adhesion was reported to be 51e95 % at SLL after laparotomic
surgeries. This incidence was 12% in laparoscopic surgeries at SLL.7
Type 2 adhesion occurred in 55e100% of patients regardless of
laparotomy or laparoscopy, and is independent of the character of
the initial adhesion.7
Adhesion formation after LM
LM has become more popular recently, although it is a highly
demanding technique. Many strategies have been developed toally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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8 cm or less in diameter are suggested for beginners.10 With more
experience, more difﬁcult cases could be attempted with accept-
ably low complication rates.11 Modiﬁcation of surgical technique
has been developed to increase feasibility of LM, such as enucle-
ation of myomas,12,13 and suturing of the myomectomy sites.14,15
Good surgical technique is related to postoperative adhesion
formation.
Post-LM adhesion rate has been reported as 28e88% during
SLL.16e19 This wide range is due tomany factors that could inﬂuence
adhesion formation after LM. Factors that might contribute to a
higher rate of adhesion after LM are: higher number of myoma
enucleated; greater length of uterine incision; large diameter of the
largest myoma; posterior location of the myoma; longer surgical
duration; and more surgical knots on myomectomy incision
wounds.18,20e23 Therefore, it is suggested that anti-adhesion de-
vices or techniques are important in LM. However, due to the
multiple factors that could inﬂuence the development of post-LM
adhesion, it is difﬁcult to evaluate the exact efﬁciencies of these
antiadhesion devices or techniques.
Apart from adhesion formation after LM, scars could appear over
the myomectomy sites that cause deformity of uterus with un-
known signiﬁcance. Kumakiri et al24 reported an incidence of 9.2%
of this so-called scarred uterus in 692 patients at SLL after LM.
Scarred uterus was more likely to occur in patients with preoper-
ative deformed endometrium, complete myometrial penetration of
myoma, or multiple enucleated myoma during the operation.
Application of adhesion barriers such as Interceed, Sepraﬁlm, or
hemostatic preparations such as ﬁbrin glue or sheets has no in-
ﬂuence on scar formation.24
Adhesion prevention devices
Surgical techniques
Some basic principles during surgery are critical in reducing
postoperative adhesions. Meticulous surgical technique in
handling tissues, diligence in hemostasis, and avoiding exposure
to foreign bodies and drying of tissue are essential. Infection,
inﬂammation, and angiogenesis have a corresponding propensity
for adhesion development and should be reduced as much as
possible. In laparoscopic surgery, reducing pressure and duration
of pneumoperitoneum could decrease adhesion formation.25 In
LM, several studies show that suture technique is closely related
to adhesion formation. Pellicano et al21 has reported that adhe-
sion formation in patients who received subserous sutures was
signiﬁcantly lower compared with patients with a ﬁgure-8 stitch
over the myomectomy sites. In a multicentre randomized study
on 330 laparoscopic surgeries, the antiadhesive 4% icodextrin
solution showed no efﬁcacy on adhesion prevention. Instead,
length of uterine incision and number of suture knots were
signiﬁcantly associated with de novo adhesion formation.22 In 296
women who received SLL after LM, Kumakiri et al23 reported that
the number of enucleated subserous myoma had an odds ratio of
3.29, and protruding wound an odds ratio of 2.53 on the
formation of postoperative adhesion. Good suture technique to
resume a smooth serosa surface over the myomectomy incision
wound is necessary to reduce postoperative adhesion formation
after LM.
Mechanical barriers
Liquid or membrane mechanical barriers may prevent post-
operative peritoneal adhesion formation by keeping peritoneal
surfaces separate during the critical period of 5e7 days followinginjury. The results search on PubMed using keywords “LM” and
“SLL”, giving the efﬁciencies of post-LM adhesion prevention
on currently commercial antiadhesive products, is shown in
Table 1.16e23,27,29,31,34,38e40
Prior to the era of well-established adhesion prevention de-
vices, crystalloids such as saline, lactated Ringer’s solution, and
dextran solution were used to prevent adhesion. The injured
surfaces were separated by the mechanism of hydroﬂotation or
siliconizing effect. However, these solutions are rapidly absorbed
and the results of adhesion prevention are either inconsistent or
disappointing.26,27
Oxidized cellulose
The biodegradable oxidized regenerated cellulose Interceed
(Johnson and Johnson Medical, Cincinnati, OH, USA) is the ﬁrst
commercial antiadhesive agent used in LM to prevent post-
operative de-novo adhesion.17,27 It was approved for abdominale
pelvic use in European CE Mark and in Asia, but only for
laparotomic use by the USA Food and Drug Administration (FDA).
It is effective in preventing adhesions but only when there is no
blood or excessive peritoneal ﬂuid. However, in a prospective,
nonrandomized study including 372 women, Interceed was re-
ported as effective as other adhesion prevention agents under
good surgical technique.28 In a study including 108 patients, the
incidence of postoperative adhesion was 38% with the applica-
tion of Interceed after LM.23 Other factors such as protruding
wound, number of enucleated subserosal myomas, and the
diameter of the largest myoma were also associated with post-
operative wound adhesion.23 Interceed is equally effective in
different types of myomectomy, laparoscopic, or laparotomy. In
an observational study including 694 women receiving either
myomectomy or LM with or without Interceed, adhesion rate
was higher in laparotomy without barrier (28.1%) compared with
laparoscopy with no barrier (22.6%), followed by laparotomy
with barrier (22%) and laparoscopy with barrier (15.9%).29
Although the differences among these groups were small and
with no signiﬁcance, it was reported that adhesions at SLL were
predominant ﬁlmy and organized with Interceed, but more
cohesive without Interceed.29
Natural glycosaminoglycan gel
Cross-linked hyaluronic acid, a natural glycosaminoglycan gel
(Hyalobarrier; Fidia Advanced Biopolymers, Abano Terme, Padova,
Italy), is a liquid barrier that has a longer residence time in the
abdominal cavity. It is approved for abdomino-pelvic use in Europe
and Asia. Hyaluronic acid gel was reported effective in preventing
post-LM adhesion formation in a randomized control study
including 36 infertile women. This study also showed a better
adhesion prevention outcome with subserous suture compared
with interrupted ﬁgure-8 stitch at the myomectomy sites.21 Preg-
nancy rates at 1-year follow-up showed parallel results with the
antiadhesive outcome.30 However, in another study including
52 LM patients, the number of patients with an antiadhesive effect
of hyaluronic acid was not as signiﬁcant, but the severity of post-
operative adhesion was signiﬁcantly lower in the hyaluronic acid
gel group.31
Hyaluronic acid-carboxymethylcellulose ﬁlm
Hyaluronic acid-carboxymethylcellulose ﬁlm (Sepraﬁlm; Gen-
zyme Corporation, Cambridge, MA, USA) was approved for
abdomino-pelvic use in Europe and Asia, but it was only approved
for laparotomy use in the USA. It is completely biodegradable and
Table 1
Summary of studies with or without an application of adhesion barriers in laparoscopic myomectomy followed with a second look laparoscopy.
Year of
publication
Case no. Adhesion barrier Period between
LM and SLL
Adhesion at SLL OR (95% CI)
Hasson et al27 1992 24 LRS or dextran,
promethazine,
dexamethasone
solution,
or Interceed
3.4 wk 66%
(21% minimal, 46%
moderate or extensive)
Keckstein et al16 1994 22 No treatment NA 28%
Mais et al17 1995 50 Interceed vs.
no treatment
12e14 wk Interceed: 10/25; 40%
No treatment: 22/25; 88%
0.45 (0.18,1.15)
Dubuisso et al18 1998 45 No treatment 14.6  13.3
(range, 0.6e49.4) mo
Myomectomy site: 35.6%
Adnexal site: 24.4%
Takeuchi et al20 2002 51 Fibrin glue spray NA 29.4%
Malzoni et al19 2003 18 No treatment NA Myomectomy site: 33.3%
Adnexal site: 0%
Pellicano et al21 2003 36 Hyalobarrier
vs. no treatment
60e90 d Hyalobarrier: 5/18; 27.8%
Figure-8 suture: 44.4%
Subcutaneous suture: 11%
No treatment: 14/18; 77.8%
Figure-8 suture: 89%
Subcutaneous suture: 66.7%
0.36 (0.11, 1.20)
Mettler et al39 2004 40 (initial including
cases: 79.7% LSC)
SprayGel vs.
no treatment
3e16 wk SprayGel: 15/22; 68.2%
No treatment: 16/18; 88.9%
0.77 (0.30, 1.96)
Takeuchi et al38 2005 91 Fibrin gel vs.
Fibrin sheet
vs. no treatment
NA Myomectomy site:
Fibrin gel: 10/29; 34.5%
Fibrin sheet: 20/30; 66.7%
No treatment: 20/32; 62.5%
(p < 0.05)
Adnexal site:
Fibrin gel: 2/29; 6.8%
Fibrin sheet: 5/30; 16.7%
No treatment: 4/30; 12.5%
Myomectomy site:
Fibrin gel: 0.55
(0.22, 1.37)
Fibrin sheet: 1.07
(0.48, 2.36)
Adnexal site:
Fibrin gel: 0.55
(0.09, 3.24)
Fibrin sheet: 1.33
(0.33, 5.44)
Mais et al31 2006 43 Hyalobarrier vs.
no treatment
12e14 wk Hyalobarrier: 8/21; 38.1%
No treatment: 13/22; 59.1%
0.64 (0.22, 1.87)
Mettler et al40 2008 58 (initial including
cases 67.6% LSC)
Hydrogel, (CoSeal,
surgical sealant) vs. LRS
8e10 wk Hydrogel: 13/38; 34.2%
Control: 13/20; 65%
0.53 (0.21, 1.35)
Takeuchi et al28 2008 372 Fibrin glue (n ¼ 58) vs.
Fibrin sheath (n ¼ 73) vs.
Sepraﬁlm (n ¼ 114) vs.
Interceed (n ¼ 66) vs.
no treatment (n ¼ 61)
NA Myomectomy site: 37.9%
Adnexal site: 8.9%
Tinelli et al29 2011 275 Interceed vs.
no treatment
Within 6 y Interceed: 15.9% (25/138)
No treatment: 22.6% (31/137)
0.80 (0.45, 1.43)
Fossum et al34 2011 41 Sepraspray (n ¼ 21) vs.
no treatment (n ¼ 20)
4e12 wk Change of mAFS score
over total uterus
Sepraspray: 0.68
No treatment: 1.56
Trew et al22 2011 254 Adept (n ¼ 120) vs.
LRS (n ¼ 134)
28e112 d 75.4%, no difference in
both groups
mAFS score at posterior
myomectomy site:
Adept (n ¼ 51): 5.04
LRS (n ¼ 48): 2.71 (p < 0.007)
Kumakiri et al23 2012 108 Interceed 6.6 (CI: 5.6e9.2)
mo
38%
CI ¼ conﬁdence interval; LSC ¼ laparoscopic surgery; LRS ¼ lactated Ringer’s solution; mAFS ¼ modiﬁed American Fertility Society; NA ¼ not applicable; OR ¼ odds ratio;
SLL ¼ second look laparoscopy.
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icant impairment of anastomoses, and should not be applied to
anastomosis cases.32 Sepraﬁlm is brittle and sticky, and requires
technical skill and experience for application during laparoscopic
surgery.33 With successful application, Sepraﬁlm is as effective as
Interceed and ﬁbrin sealant in preventing postoperative adhesion
after LM.28 Based on the difﬁculty of Sepraﬁlm application during
laparoscopic surgery, a modiﬁed hyaluronic acid and carboxy-
methylcellulose powder with special application device, Sepra-
spray (Genzyme Corporation, Cambridge, MA, USA) was invented. A
pilot study of Sepraspray failed to document its antiadhesive ef-
fect34 and it is no longer used.Icodextrin
Icodextrin 4% solution (Adept; Baxter Healthcare, Deerﬁeld,
IL, USA) is a liquid barrier that could remain in the abdominal
cavity for a longer period35 and has the advantage of easy
application during laparoscopic surgery.36 It was approved by
the FDA in 2006 for using in gynecologic laparoscopy, and is the
only FDA approved agent for use as an antiadhesive for gyne-
cologic laparoscopy. The antiadhesive effect of Icodextrin was
reported as not clinically effective in a randomized study
including 264 women.22 This could be due to multiple factors
that inﬂuence adhesion formation after LM that are statistically
P.-L. Torng / Gynecology and Minimally Invasive Therapy 3 (2014) 7e1110signiﬁcantly related to adhesion formation, such as surgery
duration, blood loss, number and size of incisions, suturing, and
number of knots. However, Adept is still signiﬁcantly effective at
sites with frequent postoperative de novo adhesion formation,
such as posterior uterus.22
Other biological products
Some biological products generally used in other clinical con-
ditions have been applied to LM as adhesion prevention agents.
Fibrin glue (Beriplast; CSL Behring, Tokyo, Japan) with two solu-
tions, ﬁbrinogen and thrombin, is commonly used as a hemostatic
agent and tissue sealant. It is used with the goal of preventing
excess blood loss and as suture support during surgical repair.37
Fibrin glue was found effective in preventing post-LM adhesion.38
Another hemostatic agent, Fibrin sheath (Tacho Comb; Tokyo,
Japan), however, was ineffective in preventing post-myomectomy
site adhesion.28 Synthetic polyethylene glycol polymer hydrogel
solutions, such as SprayGel (Conﬂuent Surgical Inc., Waltham, MA,
USA) and CoSeal surgical sealant (Angiotech Pharmaceuticals, Inc.,
Vancouver, Canada) are used for pericardial adhesion prevention. A
Phase III trial and a multicenter randomized study that included
patients with myomectomy as well as LM showed that both prod-
ucts are effective but are not signiﬁcant in reducing adhesion.39,40
Overall, these results suggest that good surgical technique alone
is insufﬁcient to prevent adhesion formation. Available anti-
adhesion barriers in current use are mostly effective in reducing
post-LM wound adhesion.
Fertility outcome after myomectomy
Adhesion formation after myomectomy could contribute to
decrease fertility. Dubisson et al18 recommend a systematically SLL
after LM in patients desiring pregnancy. A lower adhesion rate was
found during the third-look procedure (such as laparoscopy or
cesarean section) in women who received adhesion lysis in SLL
after LM.4 However, adhesion lysis during SLL found no additional
beneﬁt in increasing the subsequent pregnancy rate.41 Therefore,
the exact inﬂuence of post-LM adhesion to pregnancy outcome is
still unknown.
Apart from postoperative adhesion that might decrease fertility,
the location of myoma is another important factor that could affect
fertility. Submucosal myomas could decrease fertility outcomes and
confer surgical removal. Subserosal myomas are unlikely to affect
fertility and do not confer a beneﬁt on removal. Intramural myomas
appear to decrease fertility, and the results of removal are still
unclear.42 The type of surgery for myomectomy is another factor
that could inﬂuence fertility outcome. Laparoscopic myomectomy
confer better beneﬁt compared with laparotomic or mini-
laparotomic myomectomy. In 136 women with symptomatic my-
oma or unexplained infertility, the cumulative pregnancy rate was
higher with LM compared with minilaparotomic myomectomy
(52.9% vs. 38.2% after 15 months of follow-up).43 However, the
cumulative pregnancy rate after LM was only 26.7% in womenwith
unexplained infertility versus 73.7% in women without unex-
plained infertility,43 suggesting that myoma is not an isolated factor
interfering with fertility, and the beneﬁt of myomectomy is difﬁcult
to count in women who deserve for pregnancy after surgery. More
recently, with an assisted reproductive technique and longer
follow-up period after LM, pregnancy rate among infertile women
could rise as high as 56e58%.44 With moremeticulous laparoscopic
suture technique, less traumatic instruments, and more advanced
feasibility such as robot-assisted surgery, pregnancy rates after LM
could be even higher, and was reported as 69e74% among infertile
women.11,29,45The beneﬁt of using antiadhesive materials after LM in preg-
nancy outcome is rarely reported. The only literature reported was
on autocrosslinked hyaluronic acid gel in infertile women after
LM.21 In nine women who received subserous suture at myoma
incision wound followed by hyaluronic acid gel as an adhesion
barrier, the pregnancy rate was 100% at 1 year post operation. By
comparison, the pregnancy rate in nine women with hyaluronic
acid gel and ﬁgure-8 stitch at the myoma incision wound were
55.5%. The result was similar to the nine women with subserous
suture without hyaluronic acid gel. Pregnancy rate was only 22.2%
in the other nine women who received ﬁgure-8 stitch on incision
wound and no hyaluronic acid gel.30Conclusion
Post-LM adhesion formation is not uncommon and could lead to
a poor pregnancy outcome. Apart from a good surgical technique,
the application of antiadhesion materials after LM is effective in
reducing adhesion formation at SLL. However, more randomized
prospective trails are required to establish the best role of different
agents together with intraoperative technique to prevent post-LM
adhesion formation.References
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